open access

Vol 21, No 1 (2017)
Published online: 2017-03-30
Get Citation

Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym

Krystyna Widecka, Filip M. Szymański, Krzysztof J. Filipiak, Jacek Imiela, Beata Wożakowska-Kapłon, Eugeniusz J. Kucharz, Artur Mamcarz, Jacek Manitius, Andrzej Tykarski
DOI: 10.5603/AH.2017.0001
Arterial Hypertension 2017;21(1):1-9.

open access

Vol 21, No 1 (2017)
Published online: 2017-03-30


Not available


Not available
Get Citation
About this article

Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym


Arterial Hypertension


Vol 21, No 1 (2017)

Article type




Published online


Page views


Article views/downloads




Bibliographic record

Arterial Hypertension 2017;21(1):1-9.


Krystyna Widecka
Filip M. Szymański
Krzysztof J. Filipiak
Jacek Imiela
Beata Wożakowska-Kapłon
Eugeniusz J. Kucharz
Artur Mamcarz
Jacek Manitius
Andrzej Tykarski

References (52)
  1. Maiuolo J, Oppedisano F, Gratteri S, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016; 213: 8–14.
  2. Dalbeth N, Merriman T, Stamp L. Gout. The Lancet. 2016; 388(10055): 2039–2052.
  3. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000; 27(6): 1501–1505.
  4. Norvik JV, Storhaug HM, Ytrehus K, et al. Overweight modifies the longitudinal association between uric acid and some components of the metabolic syndrome: The Tromsø Study. BMC Cardiovasc Disord. 2016; 16: 85–98.
  5. Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases. 2014; 73(8): 1470–1476.
  6. Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014; 40(2): 155–175.
  7. Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004; 4: 9.
  8. Qiu L, Cheng Xq, Wu J, et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health. 2013; 13: 664.
  9. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006; 48(6): 1031–1036.
  10. Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens. 2007; 25(8): 1583–1589.
  11. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med. 1993; 14(6): 615–631.
  12. Ruggiero C, Cherubini A, Lauretani F, et al. Uric acid and dementia in community-dwelling older persons. Dement Geriatr Cogn Disord. 2009; 27(4): 382–389.
  13. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17): 1811–1821.
  14. Glantzounis GK, Tsimoyiannis EC, Kappas AM, et al. Uric acid and oxidative stress. Curr Pharm Des. 2005; 11(32): 4145–4151.
  15. Abeles AM. Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep. 2015; 17(3): 13.
  16. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6): 608–619.
  17. Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum. 2008; 58(2): 623–630.
  18. Puddu P, Puddu GM, Cravero E, et al. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol. 2012; 59(3): 235–242.
  19. Lee JE, Kim YG, Choi YH, et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006; 47(5): 962–967.
  20. Brand FN, McGee DL, Kannel WB, et al. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol. 1985; 121(1): 11–18.
  21. Ndrepepa G, Braun S, Haase HU, et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol. 2012; 109(9): 1260–1265.
  22. Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. 1998; 95(2): 675–680.
  23. Spitsin SV, Scott GS, Mikheeva T, et al. Comparison of uric acid and ascorbic acid in protection against EAE. Free Radic Biol Med. 2002; 33(10): 1363–1371.
  24. Chamorro A, Obach V, Cervera A, et al. Prognostic Significance of Uric Acid Serum Concentration in Patients With Acute Ischemic Stroke. Stroke. 2002; 33(4): 1048–1052.
  25. Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol. 2005; 9(3): 195–205.
  26. Perez-Ruiz F, Becker MA. Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015; 31 Suppl 2: 9–14.
  27. Kucharz EJ. Chronic inflammation-enhanced atherosclerosis: can we consider it as a new clinical syndrome? Med Hypotheses. 2012; 78(3): 396–397.
  28. Amaro S, Soy D, Obach V, et al. A Pilot Study of Dual Treatment With Recombinant Tissue Plasminogen Activator and Uric Acid in Acute Ischemic Stroke. Stroke. 2007; 38(7): 2173–2175.
  29. Duan W, Ladenheim B, Cutler RG, et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem. 2002; 80(1): 101–110.
  30. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6): 608–619.
  31. Imaram W, Gersch C, Kim KM, et al. Radicals in the reaction between peroxynitrite and uric acid identified by electron spin resonance spectroscopy and liquid chromatography mass spectrometry. Free Radic Biol Med. 2010; 49(2): 275–281.
  32. Akkineni R, Tapp S, Tosteson ANA, et al. Treatment of asymptomatic hyperuricemia and prevention of vascular disease: a decision analytic approach. J Rheumatol. 2014; 41(4): 739–748.
  33. Widecka K, Grodzicki T, Narkiewicz K, et al. Zasady postępowania w nadciśnieniu tętniczym - 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze. 2011; 15: 55–82.
  34. Mancia G, Fagard R, Narkiewicz K, et al. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Nadciśnienie Tętnicze. 2013; 17(2): 69–168.
  35. Tykarski A, Narkiewicz K, Gaciong Z, et al. 2015 Guidelines for the Management of Hypertension. Part 1–7. Recommendations of the Polish Society of Hypertension. Arterial Hypertens. 2015; 19(2): 53–83.
  36. Høieggen A, Alderman MH, Kjeldsen SE, et al. LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65(3): 1041–1049.
  37. Armstrong C. Joint National Committee. JNC 8 guidelines for the management of hypertension in adults. Am Fam Physician. 2014; 90(7): 503–4.
  38. Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev. 2011; 19(6): 265–271.
  39. Milurit - charakterystyka produktu leczniczego. lecznicze/charakterystyka-produktów leczniczych.
  40. Seth R, Kydd A, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database of Systematic Reviews. 2014.
  41. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23): 2450–2461.
  42. Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford). 2009; 48(7): 804–806.
  43. Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015; 74(7): 1368–1372.
  44. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013; 15(6): 435–442.
  45. Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Ann Med. 2017; 49(2): 142–156.
  46. Deng G, Qiu Z, Li D, et al. Effects of Allopurinol on Arterial Stiffness: A Meta-Analysis of Randomized Controlled Trials. Med Sci Monit. 2016; 22: 1389–1397.
  47. Ekici B, Kütük U, Alhan A, et al. The relationship between serum uric acid levels and angiographic severity of coronary heart disease. Kardiol Pol. 2015; 73(7): 533–538.
  48. Kumar A, Edward N, White MI, et al. Allopurinol, erythema multiforme, and renal insufficiency. BMJ. 1996; 312(7024): 173–174.
  49. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003; 349(17): 1647–1655.
  50. Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012; 64(8): 2529–2536.
  51. Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006; 40(12): 2187–2194.
  52. Adenuric - charakterystyka produktu leczniczego. lecznicze/charakterystyka-produktów leczniczych.


Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: